Search results
Replimune (REPL) Gains on Positive Data From Melanoma Study
Zacks· 2 days agoFree Report) announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ (BMY Quick ...
Dividends Are a Benefit, But Only From Companies That Can Afford to Pay Them | Investing.com
Investing.com· 4 days agoFew financial topics have been the subject of more articles than dividend investing, and for good...
The 5 Stocks Defining 'The Year Of The Dividend' In 2024
Benzinga via Yahoo Finance· 5 days agoReinvested stock dividends have significantly influenced the total return of the S&P 500 since 1927....
Buy Alert: 3 Penny Stocks That Will Explode in 2024
InvestorPlace· 4 days agoWhen the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind....
Replimune up 30% on results for RP1 combo in melanoma (NASDAQ:REPL)
Seeking Alpha· 2 days agoReplimmune Group reports positive results in melanoma patients who failed on PD-1 inhibitors,...
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Benzinga via Yahoo Finance· 2 days agoBristol-Myers Squibb Co’s (NYSE:BMY) Nivolumab, sold under the brand name Opdivo, is an anti-cancer...
Geron surges after winning first US FDA approval for blood disorder drug
Reuters· 1 day ago, opens new tab surged more than 30% on Friday, a day after the company gained its first approval...
Goldman cuts 2seventy bio to neutral, cites competition concerns (NASDAQ:TSVT)
Seeking Alpha· 2 days agoGoldman Sachs has downgraded 2seventy bio (TSVT) to neutral, citing competition concerns. Read more here.
Geron surges after winning first US FDA approval for blood disorder drug By Reuters
Investing.com· 2 days agoThe health regulator's nod allows the injectable drug, branded as Rytelo, to be used for treating...
2 No-Brainer Dividend Stocks You Can Buy With $100 in June | The Motley Fool
The Motley Fool· 6 days agoFrom 1973 through 2023, the average dividend-paying stock in the S&P 500 index delivered a 9.17%...